CRMD vs. SLDB, NATR, BDTX, AQST, CHMA, MIRM, CALT, PRTA, SAVA, and COLL
Should you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Solid Biosciences (SLDB), Nature's Sunshine Products (NATR), Black Diamond Therapeutics (BDTX), Aquestive Therapeutics (AQST), Chiasma (CHMA), Mirum Pharmaceuticals (MIRM), Calliditas Therapeutics AB (publ) (CALT), Prothena (PRTA), Cassava Sciences (SAVA), and Collegium Pharmaceutical (COLL). These companies are all part of the "medical" sector.
CorMedix (NASDAQ:CRMD) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.
CorMedix presently has a consensus target price of $13.00, suggesting a potential upside of 146.68%. Solid Biosciences has a consensus target price of $16.00, suggesting a potential upside of 93.70%. Given CorMedix's stronger consensus rating and higher possible upside, equities analysts plainly believe CorMedix is more favorable than Solid Biosciences.
34.2% of CorMedix shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 3.6% of CorMedix shares are owned by company insiders. Comparatively, 13.6% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Solid Biosciences had 4 more articles in the media than CorMedix. MarketBeat recorded 7 mentions for Solid Biosciences and 3 mentions for CorMedix. CorMedix's average media sentiment score of 1.07 beat Solid Biosciences' score of 0.40 indicating that CorMedix is being referred to more favorably in the media.
Solid Biosciences received 239 more outperform votes than CorMedix when rated by MarketBeat users. However, 71.43% of users gave CorMedix an outperform vote while only 67.55% of users gave Solid Biosciences an outperform vote.
CorMedix has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500.
CorMedix has higher earnings, but lower revenue than Solid Biosciences. CorMedix is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.
Solid Biosciences' return on equity of -55.94% beat CorMedix's return on equity.
Summary
Solid Biosciences beats CorMedix on 10 of the 17 factors compared between the two stocks.
Get CorMedix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CorMedix Competitors List
Related Companies and Tools
